05/28/2026
As the treatment landscape for transthyretin amyloid cardiomyopathy (ATTR CM) evolves, what should be on clinicians’ radar?
In this American College of Cardiology CardiaCast episode, expert faculty Sarah Cuddy, MBBCh, and Prem Soman, MD, PhD, break down the latest advances presented at ACC.26, including:
▪️Late breaking data from advanced clinical trials evaluating currently available disease modifying therapies
▪️Emerging evidence that is reshaping treatment selection, with insights on efficacy, safety, and patient specific considerations
▪️Key takeaways for clinical decision making
▪️Practical strategies for integrating new findings into real world practice to improve outcomes
🎧 Tune in for a concise, expert led discussion on how the latest data are translating into more personalized care for patients with ATTR CM.
This activity is supported by an educational grant from BridgeBio and developed by Med-IQ in collaboration with the American College of Cardiology.